CPRX Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®
EN
06/10/2020

Underlying

CPRXCatalyst Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Catalyst Pharmaceuticals

 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full...

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMR...

February 25, 2026 1 EN
 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Gl...

Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare...

February 24, 2026 1 EN
 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 F...

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2025 fina...

February 11, 2026 1 EN
 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 L...

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
CPRX Catalyst Pharma...

The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugur...

The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the...

January 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch